← All trials
NCT04448119
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 16, 2020
- Primary completion
- Mar 31, 2021
- Completion date
- Mar 31, 2021
- First posted
- Jun 25, 2020
- Last posted
- Oct 23, 2020
- Enrollment
- 760
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Appili Therapeutics Inc.Lead sponsor
- Mount Sinai Hospital, CanadaCollaborator
- Mount Sinai Hospital, CanadaOverall official - principal investigator
- University of TorontoCollaborator
- University of TorontoCollaborator
- University of TorontoCollaborator
- Applied Health Research CentreCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.